RxDoctor Payments Data

Paul Meltzer, MD

Cardiology · Santa Ana, CANPI 1982609145

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations.

$2,313in general payments, 2019–2025

Across 127 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$369
  • Johnson & Johnson$355
  • Pfizer$206
  • Merck$185
  • E.r. Squibb & Sons, L.L.C.$178
  • Novo Nordisk$147
  • plus $873 from 15 others

What the payments were for

  • Food & beverage$2,25798%
  • Education$562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,313 in reported general payments places this provider in the 70th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$442,218
Medicare patients
409
Services billed
2,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban401$516,379
EntrestoSacubitril/Valsartan174$210,756
XareltoRivaroxaban91$107,577
FarxigaDapagliflozin Propanediol79$71,795
Repatha SureclickEvolocumab91$70,031
JardianceEmpagliflozin62$65,686
VascepaIcosapent Ethyl25$21,694
BrilintaTicagrelor19$18,003
Praluent PenAlirocumab15$13,591
Ezetimibe342$9,854
NexlizetBempedoic Acid/Ezetimibe13$8,813
Rosuvastatin Calcium396$7,692
Atorvastatin Calcium574$6,449
Metoprolol Succinate463$5,512
Icosapent Ethyl20$4,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$206$516,379401 claims
NovartisEntresto$144$210,756174 claims
Johnson & JohnsonXarelto$355$107,57791 claims
AstraZenecaFarxiga, Brilinta$43$89,79798 claims
Boehringer IngelheimJardiance$127$65,68662 claims
Esperion Therapeutics, Inc.Nexlizet$18$8,81313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 156 cardiology providers in California.

Other cardiology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →